Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 03, 2022 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose to Present at 2022 RBC Capital Markets Global Healthcare Conference

SAN DIEGO and TORONTO, May 03, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
May 02, 2022 16:10 ET | Source: Aptose Biosciences, Inc.

Luxeptinib Preclinical Data Extend Potential Applications from Oncology to Inflammation

SAN DIEGO and TORONTO, May 02, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
April 25, 2022 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose to Report First Quarter 2022 Financial Results and Hold Conference Call on Monday, May 9, 2022

SAN DIEGO and TORONTO, April 25, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage precision oncology company developing highly differentiated oral kinase...
April 07, 2022 07:00 ET | Source: Aptose Biosciences, Inc.

Aptose Announces Executive Management Changes

─ Appoints Philippe Ledru as Chief Commercial Officer ─ ─ Announces resignation of CFO/CBO Jotin Marango, MD, PhD ─ SAN DIEGO and TORONTO, April 07, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences...
March 31, 2022 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose to Present at Canaccord Genuity’s 2022 Horizons in Oncology Virtual Conference

SAN DIEGO and TORONTO, March 31, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
March 22, 2022 16:01 ET | Source: Aptose Biosciences, Inc.

Aptose Reports Results for the Fourth Quarter and Full Year 2021

- HM43239 clinical remission at 120mg expands list of potential treatable AML populations - - On track to initiate genotype-enriched expansion program for HM43239 in 2H22 - - Cash runway...
March 08, 2022 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose to Report Fourth Quarter and Full Year 2021 Financial Results and Hold Conference Call on Tuesday, March 22, 2022

SAN DIEGO and TORONTO, March 08, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage precision oncology company developing highly differentiated oral kinase...
March 01, 2022 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose to Present at Oppenheimer’s 32nd Annual Healthcare Conference

SAN DIEGO and TORONTO, March 01, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
December 29, 2021 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose to Participate in Two Biotech Events in January 2022

— H.C. Wainwright BIOCONNECT Virtual Conference — — 11th Annual LifeSci Partners Corporate Access Event — SAN DIEGO and TORONTO, Dec. 29, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc....
December 20, 2021 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose Provides Update on APTO-253 Program

-- Clinical development of the MYC repressor APTO-253 will be discontinued -- -- Company will focus on advancing kinome inhibitor pipeline -- SAN DIEGO and TORONTO, Dec. 20, 2021 (GLOBE NEWSWIRE)...